Health ministers from EU member states called for action to “enhance access to innovative medicines” following a Council meeting on June 21, when they agreed to continue work on improving health policy coordination across the bloc. Health must be “kept as a priority” by the new European Commission that is shortly due to start a five-year term, following the June EU elections, ministers said, setting out the key areas where they want the incoming commission to concentrate its efforts. Read More
U.K scientists and ethicists have drawn up a code of practice for research in stem cell-derived embryo models, filling a governance gap that has opened up as these organoids have become more sophisticated and increasingly resemble their natural counterparts. “Synthetic” embryos now have the ability to organize into complex structures that approximate aspects of early human development, such as a beating heart, complex neural structures capable of signaling, sensory perception and limb-like structures. Read More
Seoul, South Korea-based Genexine Co. Ltd. plans to merge with privately held EPD Biotherapeutics Co. Ltd. by October 2024 to build a pipeline of novel targeted protein degradation therapeutics with EPD Bio’s BioPROTAC platform technology. Read More
Biopharma financings reached $70.09 billion in the first half of 2024, a 129% increase from the $30.57 billion raised in the first half of 2023. At more than $70 billion, this year's financings are already approaching the full-year total of $70.97 billion for 2023. June saw $7.57 billion in total financings, a decrease from $9.15 billion in May. Read More
Scientists at the University of Washington have engineered human plasma B cells modified to express long-lasting bispecific antibodies that could be used to treat leukemia without requiring continuous dosing. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Apollomics, Aptamer, Astrazeneca, Endopure, GB, Glycotope, Pentixapharm, Scilex, Semnur. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Eleva, Eli Lilly, Full-Life, Gyre, Regeneron, Sanofi. Read More
